摘要
分化型甲状腺癌(DTC)患者常规随访及行131I治疗时,须停用甲状腺素。停用甲状腺素而引发的甲状腺功能减退症状可显著影响DTC患者的生活质量。使用重组人促甲状腺激素(rhTSH)辅助DTC患者的随访及131I治疗,患者不须停用甲状腺素,因此可有效地避免因停用甲状腺素对患者生活质量的影响。本文就rhTSH在DTC诊治中的应用作一综述。
Traditionally, during the follow-up and in order to receive ^131I therapy, patients with differentiated thyroid carcinoma （DTC） have to withdraw from using thyroid hormone. The hypothyroidism induced by hormone withdrawal can negatively affect the quality-of-life （QOL） of DTC patients. Without the hormone withdrawal, recombinant human thyroid-stimulating hormone-aided management of DTC patients can effectively obviate the consequences of hypothyroidism. This review will focus on the clinical application of recombinant human thyroid-stimulating hor- mone （rhTSH） in the management of DTC patients.
出处
《生物医学工程学杂志》
EI
CAS
CSCD
北大核心
2012年第3期588-592,共5页
Journal of Biomedical Engineering
基金
国家自然科学基金资助项目(30870724
81071184)
关键词
分化型甲状腺癌
重组人促甲状腺激素
诊断
治疗
Differentiated thyroid carcinoma （DTC）
Recombinant human thyroid-stimulating hormone （rhTSH）
Diagnosis
Therapy
